4//SEC Filing
Dalton Barbara 4
Accession 0000899243-20-008496
CIK 0001672619other
Filed
Mar 15, 8:00 PM ET
Accepted
Mar 16, 5:18 PM ET
Size
17.4 KB
Accession
0000899243-20-008496
Insider Transaction Report
Form 4
IMARA Inc.IMRA
Dalton Barbara
Director10% Owner
Transactions
- Conversion
Series Seed Preferred Stock
2020-03-16−478,749→ 0 total(indirect: By entities affiliated with Pfizer Inc.)→ Common Stock (76,003 underlying) - Award
Stock Option (right to buy)
2020-03-16+15,457→ 15,457 totalExercise: $16.00Exp: 2030-03-15→ Common Stock (15,457 underlying) - Conversion
Common Stock
2020-03-16+1,245,222→ 1,245,222 total(indirect: By entities affiliated with Pfizer Inc.) - Conversion
Series A Preferred Stock
2020-03-16−5,470,492→ 0 total(indirect: By entities affiliated with Pfizer Inc.)→ Common Stock (868,467 underlying) - Conversion
Series B Preferred Stock
2020-03-16−1,894,444→ 0 total(indirect: By entities affiliated with Pfizer Inc.)→ Common Stock (300,752 underlying) - Purchase
Common Stock
2020-03-16$16.00/sh+312,500$5,000,000→ 1,557,722 total(indirect: By entities affiliated with Pfizer Inc.)
Footnotes (5)
- [F1]On March 16, 2020, the Issuer's Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]On March 16, 2020, the Issuer's Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F3]On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F4]The reporting person is Vice President of Venture Capital at Pfizer, Inc., an affiliate of Pfizer Ventures (US) LLC. The reporting person disclaims beneficial ownership of the shares owned by the entities affiliated with Pfizer Ventures (US) LLC except to the extent of her pecuniary interest therein.
- [F5]The option vests in three equal installments on March 16, 2021, 2022 and 2023.
Documents
Issuer
IMARA Inc.
CIK 0001672619
Entity typeother
Related Parties
1- filerCIK 0001591318
Filing Metadata
- Form type
- 4
- Filed
- Mar 15, 8:00 PM ET
- Accepted
- Mar 16, 5:18 PM ET
- Size
- 17.4 KB